Primer for advisory panels
This article was originally published in The Tan Sheet
CHPA's Scientific Affairs Committee is looking into ways to help improve the advisory committee review process. The SAC is working on "a document that sort of takes...frequently asked questions, and lays out some of the basics as a primer for advisory committee members," according to Committee Chair Ed Hemwall (J&J/Merck Consumer Pharmaceuticals). SAC would seek FDA endorsement of the document and would then provide it to advisory panel members prior to meetings. The document has not yet been drafted, but its purpose would be to "make sure that committee members understand going into the room the fundamentals of OTC study," such as consumer behavior trials and advertising regulation, Hemwall said. The information would "perhaps help reduce some of the off-topic debate and uninformed speculation that often occurs at these meetings," he added...
You may also be interested in...
The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.